Rani Therapeutics Holdings (RANI) Equity Average (2021 - 2025)
Historic Equity Average for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q3 2025 value amounting to -$10.6 million.
- Rani Therapeutics Holdings' Equity Average fell 28654.3% to -$10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.6 million, marking a year-over-year decrease of 28654.3%. This contributed to the annual value of $14.5 million for FY2024, which is 7090.31% down from last year.
- Latest data reveals that Rani Therapeutics Holdings reported Equity Average of -$10.6 million as of Q3 2025, which was down 28654.3% from -$7.3 million recorded in Q2 2025.
- In the past 5 years, Rani Therapeutics Holdings' Equity Average ranged from a high of $126.6 million in Q4 2021 and a low of -$10.6 million during Q3 2025
- Its 5-year average for Equity Average is $43.5 million, with a median of $30.1 million in 2023.
- In the last 5 years, Rani Therapeutics Holdings' Equity Average skyrocketed by 220596.22% in 2022 and then crashed by 28654.3% in 2025.
- Rani Therapeutics Holdings' Equity Average (Quarter) stood at $126.6 million in 2021, then plummeted by 36.59% to $80.3 million in 2022, then plummeted by 62.48% to $30.1 million in 2023, then crashed by 84.62% to $4.6 million in 2024, then plummeted by 327.95% to -$10.6 million in 2025.
- Its Equity Average stands at -$10.6 million for Q3 2025, versus -$7.3 million for Q2 2025 and -$928000.0 for Q1 2025.